Streetbeat News

Price Targets

APLS

Wells Fargo analyst Derek Archila has maintained an Equal-Weight rating on Apellis Pharmaceuticals (NASDAQ:APLS) but has lowered the price target from $47 to $43.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 4:14 pm

CEG

B of A Securities has maintained a Neutral rating on Constellation Energy (NASDAQ:CEG) while raising the price target from $208 to $263.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 4:13 pm

AYI

Wells Fargo analyst Joseph O'Dea has maintained an Equal-Weight rating on Acuity Brands (NYSE:AYI) while raising the price target from $260 to $289.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 4:11 pm

MOS

Wells Fargo analyst Richard Garchitorena has maintained an Equal-Weight rating on Mosaic (NYSE:MOS) but has lowered the price target from $29 to $27.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 4:09 pm

CF

Wells Fargo has maintained an Overweight rating on CF Industries Holdings and raised its price target from $88 to $92, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 4:07 pm

COGT

Citigroup analyst David Lebowitz maintains a Buy rating on Cogent Biosciences and raises the price target from $13 to $15.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 4:02 pm

TRIP

Citigroup analyst Ronald Josey maintains a Neutral rating on Tripadvisor and lowers the price target from $20 to $16.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 4:00 pm

PCRX

Pacira BioSciences (NASDAQ:PCRX) has received mixed analyst ratings, with a notable decrease in the average 12-month price target from $41.29 to $30.36. Analysts have adjusted their ratings and price targets, reflecting varied expectations for the company's future performance. Despite a strong net margin and effective debt management, Pacira's revenue growth lags behind industry peers.

Portfolio Pulse from Benzinga Insights

September 24, 2024 | 4:00 pm

EL

Estee Lauder Cos (NYSE:EL) has received mixed analyst ratings over the past three months, with a recent average 12-month price target of $120.91, down from $137.97. Analysts have adjusted their ratings and price targets in response to market dynamics, with some maintaining bullish stances while others have lowered their expectations. Estee Lauder's financial performance shows a revenue growth rate of 7.26% and challenges in debt management with a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

September 24, 2024 | 4:00 pm

HD

LOW

Oppenheimer analyst Brian Nagel upgraded Lowe's Companies Inc (NYSE:LOW) from Perform to Outperform, raising the price target from $230 to $305. The upgrade is based on expected demand improvements in the home improvement sector due to moderating lending rates, with benefits likely to be seen starting in 2025. Lowe's shares rose 0.63% following the announcement.

Portfolio Pulse from Priya Nigam

September 24, 2024 | 3:58 pm